ProCE Banner Events


Caring for Patients With Cancer in a Post-COVID World: Expert Guidance on the Latest Data and Therapeutic Advances to Mitigate Infection Risk

Join expert faculty as they discuss how to integrate the latest scientific data and developments in COVID-19 prevention into optimized management approaches in patients with cancer.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Who Should Attend

This program is intended for oncology and infectious diseases specialists, including physicians and clinical pharmacists, advanced practice providers, nurses, and other healthcare professionals who care for patients with cancer at risk for severe COVID-19 outcomes.

Time and location

Friday, May 31, 2024

11:30 AM - 1:00 PM Central Time (CT)


Hilton Chicago
720 S Michigan Ave.
Chicago, Illinois 60605

Boulevard Room, Level 2

Mazyar Shadman, MD, MPH

Innovators Network Endowed Chair
Associate Professor of Hematology and Oncology
Lymphoid Malignancies and Immunotherapy 
Fred Hutch Cancer Center and University of Washington
Seattle, Washington

Shmuel Shoham, MD

Professor of Clinical Medicine
Transplant and Oncology Infectious Diseases Program
Johns Hopkins University School of Medicine
Baltimore, Maryland

Cynthia Nguyen, PharmD, BCIDP

Clinical Pharmacy Specialist, Infectious Diseases
University of Chicago Medicine
Chicago, Illinois


Registration and Lunch: 11:00 AM

Presentation: 11:30 AM

  • Welcome, introduction, and baseline assessment
  • Clinical case discussions
    • Defining the risk of severe COVID-19 outcomes in patients with cancer
    • Next-generation mAbs for COVID-19 prevention
    • Integrating mAbs into management plans for patients with cancer
  • Question and answer session


Venue Name

Hilton Chicago


Hilton Chicago
720 S Michigan Ave.
Chicago, Illinois 60605

Room Name

Boulevard Room, Level 2


Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with COVID.

Target Audience
This program is intended for oncology and infectious diseases specialists, including physicians and clinical pharmacists, advanced practice providers, nurses, and other healthcare professionals who care for cancer patients at risk for severe COVID-19 outcomes. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan COVID-19 prevention strategies for patients with cancer considering available guidelines along with new and emerging scientific data on next-generation mAbs.
  • Identify patients with cancer who can benefit from COVID-19 prophylaxis with next-generation mAbs.
  • Advance equitable access to COVID-19 prevention strategies for patients with cancer through multi-specialty and interprofessional collaboration.


Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.5 contact hours. 

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-24-017-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Joint Accreditation



NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. Full disclosure of faculty relationships will be made prior to the activity. 


Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Supported by an educational grant from AstraZeneca.

Contact Information

For customer support please click here.

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.